---
title: "Regeneron hits 52-week high after FDA approves rare bone disease drug Pasatru"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296633051.md"
description: "Regeneron rose over 2% to a 52-week high after FDA approved Pasatru for FOP, even as the company faces securities class actions over trial disclosures."
datetime: "2026-08-21T15:02:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296633051.md)
  - [en](https://longbridge.com/en/news/296633051.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296633051.md)
generator: "portal-rs"
---

# Regeneron hits 52-week high after FDA approves rare bone disease drug Pasatru

再生元制药 (REGN.US) 盘中股价创 52 周新高，涨超 2%，现报**846.515 美元**。

消息面上，公司近期获得美国 FDA 批准罕见骨病药物 Pasatru（garetosmab-grts），用于治疗成人纤维发育性骨化性肌炎（FOP）。该药物三期临床数据显示，与安慰剂相比可减少**90%-94%**的新发病灶。此外，公司二季度营收达**42.9 亿美元**，同比增长**17%**，EYLEA HD 美国销售额增长**52%**至**5.96 亿美元**。

然而，公司同时面临多项证券集体诉讼。多家律所指控再生元在 2025 年 8 月至 2026 年 5 月期间就其 Fianlimab-Libtayo 三期临床试验结果作出虚假陈述，隐瞒试验未达主要终点的风险。该消息披露后公司市值曾蒸发**110 亿美元**。投资者可于**2026 年 9 月 14 日**前申请首席原告地位。

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296847570.md)
- [Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?](https://longbridge.com/en/news/296702017.md)
- [Regeneron podcast turns science into immersive experience](https://longbridge.com/en/news/296758441.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [Vega Investment Solutions Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296891476.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**